Cardiometabolic News and Research

RSS

Six early life factors found to influence obesity risk in South Asian children

Researchers at McMaster University have identified six key factors in the first three years of life that influence the trajectory of obesity in South Asian children.

10 Apr 2025

AI-driven personalized nutrition shows promise in improving gut health

Researchers examine the impact of AI-based personalized nutrition programs on the gut microbiome of healthy individuals.

10 Apr 2025

Gut microbes and metabolites reveal how lifestyle changes help prevent type 2 diabetes

Researchers identified 502 blood metabolites linked to prediabetes and type 2 diabetes, with 143 tied to the gut microbiome. The study shows how lifestyle interventions like diet and exercise can modify metabolomic profiles to support glucose control.

9 Apr 2025

Eating ultra-processed foods may rewire your brain’s hunger and reward circuits

High intake of ultra-processed foods is linked to adverse metabolic health and microstructural brain changes in regions that control appetite and reward. These effects occur both through obesity-related pathways and independently via inflammation and dyslipidemia.

9 Apr 2025

Lack of ceramides in blood vessels could lead to obesity-related heart diseases

New research from Weill Cornell Medicine has uncovered a surprising culprit underlying cardiovascular diseases in obesity and diabetes-not the presence of certain fats, but their suppression.

8 Apr 2025

Study links gut microbe shifts in migrants to cardiovascular risk

An Amsterdam UMC-led study has found that migrants, this case from West Africa to Europe, experience a 'clear change' in their microbiome composition as compared to their non-migrant peers in West Africa, which expose them to an increase of cardiovascular disease.

8 Apr 2025

Genetic pathways explain why some people grow tall and others stay short

A landmark review in Nature Reviews Genetics dissects the rare and common genetic variants that shape human height. The paper explains how monogenic and polygenic factors converge on key growth pathways and influence disease risk.

7 Apr 2025

Bridging the digital divide to improve heart health for all

The use of technology-based health solutions, such as fitness trackers, smartwatches and mobile health apps, has shown potential to help people improve management of their cardiovascular health.

7 Apr 2025

Reducing cardiometabolic risk and inflammation with pomegranate

Pomegranate extract shows promise in lowering systolic blood pressure and inflammatory markers, highlighting its role in promoting healthy aging for adults 55+.

4 Apr 2025

American College of Physicians announces $260,000 in grants to advance equitable obesity care

Today, the American College of Physicians (ACP) announced that it has awarded a total of $260,000 in grants to support regional programs that address equity challenges in obesity care.

3 Apr 2025

Low walkability in neighborhoods associated with higher heart disease risk

Low neighborhood walkability is associated with increased risk of cardiovascular disease (CVD), according to research presented today at ESC Preventive Cardiology 2025, a scientific congress of the European Society of Cardiology (ESC).

3 Apr 2025

NYC and Baltimore scientists awarded grants for cardiovascular and diabetes research

A New York City-based physician scientist who explores ways to improve health by looking at the ways in which cells and molecules impact disease and an epidemiologist from Baltimore who has devoted her career to identifying ways to improve screening, diagnosis and patient care for people with diabetes are the most recent American Heart Association Merit Award recipients.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

What blueberries do and don’t do for your microbiome and heart

Regular blueberry consumption for 12 weeks enriched Coriobacteriales incertae sedis in the gut microbiota of older overweight adults. However, this microbial shift was not linked to significant improvements in cardiometabolic biomarkers.

31 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Scientists link emulsifiers in processed foods to allergy and immune disorders

Review identifies common food additives in ultra-processed foods—particularly emulsifiers like carrageenan and polysorbate 80—as key drivers of gut dysbiosis, inflammation, and allergic diseases by disrupting intestinal barriers and activating proinflammatory pathways.

26 Mar 2025

Addressing cardiovascular risk factors in emerging adulthood

Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and the transition from adolescence to adulthood is a key time to address these risk factors and reduce the risk of developing future cardiovascular disease, according to a new American Heart Association scientific statement published today in the Journal of the American Heart Association.

26 Mar 2025

Epigenetic scores offer new insights into cardiometabolic disease prevention

A new study explores how epigenetic markers-chemical modifications that influence gene activity-can help predict the risk of developing cardiometabolic diseases and guide personalized prevention strategies.

25 Mar 2025

US Patent Office grants Closed Loop Medicine key patents for cardiometabolic capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) therapies

Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.

25 Mar 2025

A pecan a day keeps bad cholesterol away

Daily consumption of 57g of pecans for 12 weeks improved cholesterol profiles and diet quality in adults at risk of cardiometabolic disease, without affecting vascular health. Replacing typical snacks with pecans led to higher intake of healthy fats and fiber, and reduced carbohydrate consumption.

24 Mar 2025